[
    [
        {
            "time": "",
            "original_text": "QFII、社保、年金、私募二季度都买了啥？中报揭秘它们均买入了这个板块",
            "features": {
                "keywords": [
                    "QFII",
                    "社保",
                    "年金",
                    "私募",
                    "中报",
                    "买入",
                    "板块"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "综合"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "QFII、社保、年金、私募二季度都买了啥？中报揭秘它们均买入了这个板块",
                "Correlation": 7,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 4,
                "Market_Scope": 8,
                "Time_Proximity": 7,
                "Headline_Structure": 9,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "医药行业周报: 国家医保局, 14种抗癌药将迎新一轮降价",
            "features": {
                "keywords": [
                    "医药",
                    "国家医保局",
                    "抗癌药",
                    "降价"
                ],
                "sentiment_score": -0.6,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "医药行业周报: 国家医保局, 14种抗癌药将迎新一轮降价",
                "Correlation": 8,
                "Sentiment": 3,
                "Importance": 9,
                "Impact": 8,
                "Duration": 8,
                "Entity_Density": 5,
                "Market_Scope": 9,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "【乐普医疗】中报点评：业绩持续亮眼，多条业务线将陆续迎来收获",
            "features": {
                "keywords": [
                    "乐普医疗",
                    "中报",
                    "业绩",
                    "业务线",
                    "收获"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "【乐普医疗】中报点评：业绩持续亮眼，多条业务线将陆续迎来收获",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 8,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "巨丰投顾：通讯和国企改革板块发力 沪指2700点底部仍有效",
            "features": {
                "keywords": [
                    "通讯",
                    "国企改革",
                    "板块",
                    "沪指",
                    "2700点",
                    "底部"
                ],
                "sentiment_score": 0.5,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "通讯",
                    "国企改革"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "巨丰投顾：通讯和国企改革板块发力 沪指2700点底部仍有效",
                "Correlation": 5,
                "Sentiment": 6,
                "Importance": 6,
                "Impact": 5,
                "Duration": 5,
                "Entity_Density": 3,
                "Market_Scope": 7,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "",
            "original_text": "[买入评级] 医药生物行业动态：上海带量采购分析 集中招采促进行业升级",
            "features": {
                "keywords": [
                    "医药生物",
                    "上海",
                    "带量采购",
                    "集中招采",
                    "行业升级"
                ],
                "sentiment_score": 0.8,
                "policy_related": "true",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "[买入评级] 医药生物行业动态：上海带量采购分析 集中招采促进行业升级",
                "Correlation": 8,
                "Sentiment": 6,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 6,
                "Market_Scope": 8,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "医药生物行业日报：福建通过一致性评价品种最高补助100万",
            "features": {
                "keywords": [
                    "医药生物",
                    "福建",
                    "一致性评价",
                    "补助"
                ],
                "sentiment_score": 0.7,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "医药生物行业日报：福建通过一致性评价品种最高补助100万",
                "Correlation": 7,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 5,
                "Market_Scope": 8,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 8
            }
        }
    ]
]